Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial

Aims/hypothesisHypoglycaemia during and after exercise remains a challenge. The present study evaluated the safety and efficacy of closed-loop insulin delivery during unannounced (to the closed-loop algorithm) afternoon physical activity and during the following night in young people with type 1 diabetes.MethodsA randomised, two-arm, open-label, in-hospital, crossover clinical trial was performed at a single site in Slovenia. The order was randomly determined using an automated web-based programme with randomly permuted blocks of four. Allocation assignment was not masked. Children and adolescents with type 1 diabetes who were experienced insulin pump users were eligible for the trial. During four separate in-hospital visits, the participants performed two unannounced exercise protocols: moderate intensity (55% of V⋅O2max$$ \overset{\cdot }{V}{\mathrm{O}}_{2\max } $$) and moderate intensity with integrated high-intensity sprints (55/80% of V⋅O2max$$ \overset{\cdot }{V}{\mathrm{O}}_{2\max } $$), using the same study device either for closed-loop or open-loop insulin delivery. We investigated glycaemic control during the exercise period and the following night. The closed-loop insulin delivery was applied from 15:00 h on the day of the exercise to 13:00 h on the following day.ResultsBetween 20 January and 16 June 2016, 20 eligible participants (9 female, mean age 14.2 ± 2.0 years, HbA1c 7.7 ± 0.6% [60.0 ± 6.6 mmol/mol]) were included in the trial and performed all trial-mandated activities. The median proportion of time spent in hypoglycaemia below 3.3 mmol/l was 0.00% for both treatment modalities (p = 0.7910). Use of the closed-loop insulin delivery system increased the proportion of time spent within the target glucose range of 3.9–10 mmol/l when compared with open-loop delivery: 84.1% (interquartile range 70.0–85.5) vs 68.7% (59.0–77.7), respectively (p = 0.0057), over the entire study period. This was achieved with significantly less insulin delivered via the closed-loop (p = 0.0123).Conclusions/interpretationClosed-loop insulin delivery was safe both during and after unannounced exercise protocols in the in-hospital environment, maintaining glucose values mostly within the target range without an increased risk of hypoglycaemia.Trial registrationClinicaltrials.gov NCT02657083FundingUniversity Medical Centre Ljubljana, Slovenian National Research Agency, and ISPAD Research Fellowship

[1]  Laya Ekhlaspour,et al.  Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. , 2016, The lancet. Diabetes & endocrinology.

[2]  Roman Hovorka,et al.  Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.

[3]  Tadej Battelino,et al.  MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial , 2014, Diabetes Care.

[4]  K. Albertsson-Wikland,et al.  Hormonal response during physical exercise of different intensities in adolescents with type 1 diabetes and healthy controls , 2012, Pediatric diabetes.

[5]  Tadej Battelino,et al.  Prevention of Hypoglycemia With Predictive Low Glucose Insulin Suspension in Children With Type 1 Diabetes: A Randomized Controlled Trial , 2017, Diabetes Care.

[6]  A. Jenkins,et al.  Insulin pump basal adjustment for exercise in type 1 diabetes: a randomised crossover study , 2016, Diabetologia.

[7]  Francesca Annan,et al.  Exercise management in type 1 diabetes: a consensus statement. , 2017, The lancet. Diabetes & endocrinology.

[8]  E. Atlas,et al.  MD‐Logic overnight type 1 diabetes control in home settings: A multicentre, multinational, single blind randomized trial , 2017, Diabetes, obesity & metabolism.

[9]  Ahmad Haidar,et al.  Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes , 2013, Diabetes Care.

[10]  E. Tsalikian,et al.  Effects of Moderate-to-Vigorous Intensity Physical Activity on Overnight and Next-Day Hypoglycemia in Active Adolescents With Type 1 Diabetes , 2014, Diabetes Care.

[11]  N. Bratina,et al.  Improved metabolic control in pediatric patients with type 1 diabetes: a nationwide prospective 12-year time trends analysis. , 2014, Diabetes technology & therapeutics.

[12]  Marc D Breton,et al.  Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D , 2017, Pediatric diabetes.

[13]  W. Tamborlane,et al.  Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. , 2016, Diabetes technology & therapeutics.

[14]  L. Leelarathna,et al.  Basal insulin delivery reduction for exercise in type 1 diabetes: finding the sweet spot , 2016, Diabetologia.

[15]  Ahmad Haidar,et al.  Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial , 2016, Diabetologia.

[16]  S. Berthoin,et al.  Effects of different types of acute and chronic (training) exercise on glycaemic control in type 1 diabetes mellitus: a meta-analysis. , 2012, Sports medicine.

[17]  D. Dunstan,et al.  Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association , 2016, Diabetes Care.

[18]  Roman Hovorka,et al.  Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study , 2017, The lancet. Diabetes & endocrinology.

[19]  J. Steinacker,et al.  Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients , 2015, Diabetes Care.

[20]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[21]  V. Tillmann,et al.  International Society for Pediatric and Adolescent Diabetes , 1998, Hormone Research in Paediatrics.

[22]  Howard C. Zisser,et al.  Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report , 2016, Diabetes Care.

[23]  M. Riddell,et al.  Exercise in children and adolescents with diabetes , 2008, Pediatric diabetes.

[24]  Cesar C. Palerm,et al.  Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes , 2013, Diabetes Care.

[25]  E. Atlas,et al.  Night glucose control with MD‐Logic artificial pancreas in home setting: a single blind, randomized crossover trial—interim analysis , 2014, Pediatric diabetes.

[26]  Marc D Breton,et al.  Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. , 2014, Diabetes technology & therapeutics.

[27]  M. Riddell,et al.  Exercise in children and adolescents with diabetes , 2014, Pediatric diabetes.

[28]  Darrell M. Wilson,et al.  Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes , 2015, Diabetes.

[29]  E. Atlas,et al.  MD-Logic Artificial Pancreas System: A Pilot Study in Adults with Type 1 Diabetes Mellitus Running Title: Closed-Loop System In Type 1 Diabetes , 2010 .

[30]  Claudio Cobelli,et al.  2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[31]  P. Fournier,et al.  Effectiveness of a Predictive Algorithm in the Prevention of Exercise-Induced Hypoglycemia in Type 1 Diabetes. , 2016, Diabetes technology & therapeutics.

[32]  N. Mutrie,et al.  A systematic review of physical activity and sedentary behavior intervention studies in youth with type 1 diabetes: study characteristics, intervention design, and efficacy , 2014, Pediatric diabetes.